Author + information
- Received October 14, 2018
- Revision received November 20, 2018
- Accepted November 24, 2018
- Published online January 28, 2019.
- aCenter for Care Delivery and Outcomes Research, Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota
- bBrigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School, Boston, Massachusetts
- ↵∗Address for correspondence:
Dr. Muthiah Vaduganathan, Brigham and Women’s Hospital Heart & Vascular Center, 75 Francis Street, Boston, Massachusetts.
The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering therapies that have been shown to reduce risks of heart failure (HF) events in patients with type 2 diabetes mellitus (T2DM) at high-risk for or with cardiovascular disease. The United States Food and Drug Administration has expanded the regulatory label for empagliflozin and canagliflozin for use to lower cardiovascular risk in patients with T2DM and cardiovascular disease. SGLT2 inhibitors are being actively studied in the treatment of patients with HF, including in those without diabetes mellitus. Despite the accumulating data supporting this class of therapies in HF prevention, cardiologists infrequently prescribe SGLT2 inhibitors, potentially due to lack of familiarity with their use. We provide an up-to-date practical guide highlighting important elements for treatment initiation, dosing, anticipated adverse effects, and barriers to uptake.
Dr. Vardeny is the U.S. National Lead Investigator for a trial of an SGLT2 inhibitor in heart failure, sponsored by AstraZeneca. Dr. Vaduganathan is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541); and serves on advisory boards for AstraZeneca, Bayer AG, and Baxter Healthcare.
- Received October 14, 2018.
- Revision received November 20, 2018.
- Accepted November 24, 2018.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.